-+ 0.00%
-+ 0.00%
-+ 0.00%

Regeneron Pharmaceuticals To Present New And Updated Data From Hematology Portfolio And Pipeline, At ASH 2026 Annual Meeting

Benzinga·11/19/2026 12:12:24
Listen to the news

Primary analysis from a potentially pivotal trial of Ordspono® (odronextamab) in patients with R/R marginal zone lymphoma (MZL) to be shared in an oral presentation, part of a clinical development program evaluating Ordspono across a broad spectrum of lymphoma settings

New data on Lynozyfic® (linvoseltamab) in R/R systemic light chain (AL) amyloidosis also to be shared in an oral presentation, also part of a clinical development program evaluating Lynzoyfic across a broad spectrum of multiple myeloma settings and precursor conditions

Additional presentations across a broad range of programs highlight next wave of innovation in blood disorders

TARRYTOWN, N.Y., Nov. 19, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced new and updated data from its hematology portfolio and pipeline will be shared across 14 abstracts at the American Society of Hematology (ASH) 2026 Annual Meeting, taking place from December 12-15 in New Orleans. Presentations highlight progress across several treatment approaches – including bispecific antibodies and novel siRNA therapies – for a wide range of blood cancers and disorders, including lymphoma, multiple myeloma and paroxysmal nocturnal hemoglobinuria (PNH).